Darlene Deptula-Hicks Joins Greywolf: Former CFO of Pieris Pharmaceuticals Enhances Biotech Strategy
- Darlene Deptula-Hicks previously served as CFO at Pieris Pharmaceuticals, enhancing her expertise in biotech finance.
- Her leadership at Greywolf aims to secure funding for advancing clinical trials and innovative therapies.
- Deptula-Hicks's experience positions Greywolf to address the demand for effective treatments in oncology and autoimmune diseases.
Darlene Deptula-Hicks Joins Greywolf Therapeutics as CFO: A Strategic Move for Biotech Advancement
Greywolf Therapeutics, a clinical-stage biotech firm based in Oxford, England, announces the appointment of Darlene Deptula-Hicks as its new Chief Financial Officer. With over 30 years of extensive experience in corporate finance, capital markets, and investor relations, Deptula-Hicks brings a wealth of knowledge to the company. Her previous role as CFO at F-star Therapeutics Inc. was marked by a successful NASDAQ IPO in 2020, followed by the company's sale in 2023. Peter Joyce, CEO and Co-founder of Greywolf, expresses strong optimism about her appointment, underscoring the critical importance of her background in biotech financing and public company operations as the company looks to advance its cutting-edge antigen modulation technologies.
Greywolf Therapeutics focuses on innovative antigen modulation technology aimed at directing T cells within the immune system. The company's lead product, GWRD5769, has already demonstrated promising results in a Phase I/II oncology trial, signaling its potential as a viable treatment option. Additionally, the firm is developing a second modulator, GRWD0715, which is currently in preclinical studies targeting autoimmune disorders. With Deptula-Hicks at the helm of financial strategy, Greywolf is poised to enhance its operational capabilities and secure the necessary funding to progress through crucial clinical trials. Her appointment comes at a pivotal time, as the biotech industry increasingly seeks more effective therapies to address a variety of diseases.
Deptula-Hicks's extensive experience in the biotech sector is further highlighted by her previous roles, including CFO positions at Normunity and Pieris Pharmaceuticals, as well as board memberships at Abcuro and Avacta Therapeutics. She expresses excitement about joining Greywolf, emphasizing the company's potential to meet the growing demand for innovative treatments. With her leadership, Greywolf Therapeutics aims not only to strengthen its financial foundation but also to position itself as a leader in the development of novel therapies that could transform patient care in oncology and autoimmune diseases.
In addition to its leadership changes, Greywolf's focus on antigen modulation places it at the forefront of modern therapeutic strategies. The company's innovative approach could play a significant role in addressing the urgent need for effective treatments in complex medical conditions. By combining advanced technology with seasoned financial leadership, Greywolf is set to navigate the challenges of clinical development while striving for operational excellence in the competitive biotech landscape.